Investing Profile

David Mott

InvestorVC

Private Investor at Mott Family Capital

Montana
Photo of David Mott, Investor at Mott Family Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
New Enterprise Associates (NEA) Network
33 CONNECTIONS
cb
$100K - $10.0M
$1M
14
CompanyStageDateRound SizeTotal Raised
Sagimet Biosciences
Series EAug 2019$7M
$190M
Co-investors: Robert Garland (New Enterprise Associates (NEA)), Matthew McAviney (New Enterprise Associates (NEA)), Beth Seidenberg (Kleiner Perkins)
Nightstar Therapeutics
Series CJun 2017$45M
Series BNov 2015$35M
$80M
Ardelyx
Post-IPO EquityJul 2016$110M
Post-IPO EquityJun 2015$78M
Series BAug 2011$30M
$220M
Clementia Pharmaceuticals
Venture RoundJun 2015$60M
$93M
Co-investors: David Bonita (OrbiMed), Jean-François Pariseau (Amplitude VC)
Adaptimmune
Series ASep 2014$100M
$100M
Co-investors: Ali Behbahani (New Enterprise Associates (NEA))
Cydan
Venture RoundOct 2013$10M
Venture RoundApr 2013$16M
$26M
Edimer Pharmaceuticals
Series BJul 2013$18M
$18M
Co-investors: Bernard Davitian (Omega Funds)
Prosensa
Venture RoundJan 2012€23M
€23M
General Partner New Enterprise Associates (NEA)2008 - 2020